GLOW-80: Scientific Profile
Publicado el · Actualizado el
Lyophilized blend for research use only (RUO) of four peptides, 80 mg/vial: GHK-Cu 50 mg (copper tripeptide-1), TB-500 10 mg (Thymosin β4 fragment), BPC-157 10 mg (pentadecapeptide), and KPV 10 mg (α-MSH-derived tripeptide).
GLOW is a lyophilized blend of three research peptides in fixed proportions, with 70 mg total per vial. GHK-Cu (copper tripeptide-1, Gly-His-Lys·Cu²⁺; CAS of the complex 89030-95-5, free GHK 49557-75-7), 50 mg: a modulator of gene expression (~4000 genes) that regulates the synthesis of procollagen I/III, elastin and glycosaminoglycans, acts as a cofactor of lysyl oxidase and modulates the TGF-β1/Smad2-3 pathway; it is not a direct ligand of the TGF-β receptor. BPC-157 (gastric pentadecapeptide, 15 aa, GEPPPGKPADDAGLV; CAS 137525-51-0), 10 mg: acts via the nitric oxide pathway with upregulation of VEGFR2 (angiogenesis) and a cytoprotective effect. TB-500 (Ac-LKKTETQ, N-acetylated 17-23 fragment of Thymosin β4; CAS 885340-08-9), 10 mg: a G-actin sequestrant that promotes cell migration and repair. In vitro/preclinical applications: tissue repair, angiogenesis, cell migration and extracellular matrix remodeling. Reconstitution with 3-5 mL of bacteriostatic water; store lyophilized at -20 °C and ≤30 days at 2-8 °C after reconstitution. RUO.
Mechanism of action
GLOW-80 acts through multiple synergistic mechanisms:
- Stimulation of fibroblasts: Signal peptides activate TGF-β receptors, increasing the production of procollagen I and III
- Inhibition of MMP: Fragmentos específicos bloquean metaloproteinasas (MMP-1, MMP-3) que degradan colágeno
- Copper peptides: GHK-Cu incluido activa lisil oxidasa y superóxido dismutasa, promoviendo entrecruzamiento de colágeno y defensa antioxidante
- Modulation of melanogenesis: Regulates melanin production for a more even tone
- Deep hydration: Aumenta síntesis de ácido hialurónico endógeno en la dermis
- Barrier repair: Promotes the synthesis of ceramides and epidermal lipids
Mechanism summary
GHK-Cu modulates the expression of ~4000 genes, the TGF-β1/Smad pathway and collagen/elastin synthesis (a cofactor of lysyl oxidase); BPC-157 acts via the nitric oxide pathway with upregulation of VEGFR2 (angiogenesis, cytoprotection); TB-500 sequesters G-actin and promotes cell migration and repair.
Clinical Studies (6)
There is no peer-reviewed literature on GLOW-80 as a combination. What follows is the literature for each component separately:
- About GHK-Cu: Glycyl-L-histidyl-L-lysine-Cu(2+) rescues cigarette smoking-induced skeletal muscle dysfunction via a sirtuin 1-dependent pathway (Deng, et al. · Journal of Cachexia, Sarcopenia and Muscle · 2023) PMID 36905132.
- About BPC-157: Protective effects of pentadecapeptide BPC 157 on gastric ulcer in rats (Xue, et al. · World Journal of Gastroenterology · 2004) PMID 15052688.
- About TB-500: Thymosin beta4 accelerates wound healing (Malinda, et al. · Journal of Investigative Dermatology · 1999) PMID 10469335.
- About GHK-Cu: Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. (Miller TR, et al. · Arch Facial Plast Surg · 2006) PMID 16847171.
- About BPC-157: Focus on ulcerative colitis: stable gastric pentadecapeptide BPC 157 (Sikiric, et al. · Current Medicinal Chemistry · 2012) PMID 22300085.
- About TB-500: Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications (Goldstein, et al. · Expert Opinion on Biological Therapy · 2012) PMID 22074294.
Warnings
GLOW-80 is a compound exclusively for research use (RUO); the following warnings and handling considerations apply to its use in the laboratory:
- For research use only
- Do not inject into blood vessels
- Perform a sensitivity test
- Models with known hypersensitivity to GHK-Cu, BPC-157, TB-500 or copper
- Pregnant or lactating models (insufficient data)
- Models under 18 years old
- Models with active neoplasia or a recent history of cancer
- Models with Wilson's disease or other disorders of copper metabolism
- Models with active pathological angiogenesis (proliferative retinopathy, vascularized tumors)
Technical data
- Compound type
- peptide_blend
- Storage
- -20 °C liofilizado; 2-8 °C reconstituido
- Shelf life (lyophilized)
- 18 months
- Shelf life (reconstituted)
- 21 days refrigerated
- Light-sensitive
- No
Available for research
GLOW-80 is available as a research-use-only (RUO) reagent with HPLC-verified purity and a per-batch COA:
Frequently asked questions about GLOW-80
What is GLOW-80?
Lyophilized blend for research use only (RUO) of four peptides, 80 mg/vial: GHK-Cu 50 mg (copper tripeptide-1), TB-500 10 mg (Thymosin β4 fragment), BPC-157 10 mg (pentadecapeptide), and KPV 10 mg (α-MSH-derived tripeptide).
What is the mechanism of action of GLOW-80?
GHK-Cu modulates the expression of ~4000 genes, the TGF-β1/Smad pathway and collagen/elastin synthesis (a cofactor of lysyl oxidase); BPC-157 acts via the nitric oxide pathway with upregulation of VEGFR2 (angiogenesis, cytoprotection); TB-500 sequesters G-actin and promotes cell migration and repair.
What is GLOW-80 investigated for?
In preclinical research, GLOW-80 is studied mainly in: GHK-Cu: TGF-β/integrin modulation; BPC-157: NO/VEGF pathway; TB-500: G-actin regulation. Material for scientific research use only.
How is GLOW-80 stored?
Condiciones de conservación: -20 °C liofilizado; 2-8 °C reconstituido; estabilidad liofilizado: 18 meses; una vez reconstituido: 21 días refrigerado.
What routes of administration are studied for GLOW-80?
In research models the following are described: Subcutaneous, Mesotherapy, Topical. Use is exclusively for scientific research.
What precautions should be considered with GLOW-80?
GLOW-80 is material exclusively for research. For research use only. Do not inject into blood vessels.